API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/05/01/2873660/0/en/Belite-Bio-Announces-Presentation-at-the-Association-for-Research-in-Vision-and-Ophthalmology-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/22/2850915/0/en/Belite-Bio-Announces-PMDA-Submission-of-Tinlarebant-for-Stargardt-Disease-Clinical-Trial-in-Japan.html
https://www.globenewswire.com//news-release/2023/11/06/2774071/0/en/Belite-Bio-Presents-Results-from-a-24-month-Phase-2-Study-of-Tinlarebant-in-Childhood-onset-Stargardt-Disease-at-the-AAO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/07/27/2712760/0/en/Belite-Bio-Doses-First-Subject-in-Pivotal-Phase-3-PHOENIX-Trial-Evaluating-Oral-Tinlarebant-for-GA.html
https://www.globenewswire.com/news-release/2023/07/24/2709349/0/en/Belite-Bio-Completes-Enrollment-in-Pivotal-Global-Phase-3-DRAGON-Trial-Evaluating-Oral-Tinlarebant-for-Stargardt-Disease.html
https://www.globenewswire.com/news-release/2023/04/25/2654504/0/en/Belite-Bio-Presented-18-Month-Interim-Data-from-a-24-Month-Phase-2-Study-of-Tinlarebant-in-Adolescent-Stargardt-Disease-at-the-2023-ARVO-Meeting.html
https://www.globenewswire.com/news-release/2022/11/18/2559066/0/en/Belite-Bio-Finalizes-Phase-3-Clinical-Trial-Plans-for-Advanced-Dry-AMD-Treatment-with-Tinlarebant-LBS-008.html
https://www.globenewswire.com/news-release/2022/08/22/2502141/0/en/Belite-Bio-Initiates-Pivotal-Phase-3-Clinical-Trial-of-LBS-008-in-Stargardt-Disease-in-the-U-S.html